| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $1,052,104 | 5 | 100 |
| Ticktin Robert | General Counsel & COO | 0 | $0 | 1 | $24,651 | $-24,651 |
| Carulli Michael | Chief Financial Officer | 0 | $0 | 1 | $30,077 | $-30,077 |
| Jalota Deepika | Chief Development Officer | 0 | $0 | 1 | $35,198 | $-35,198 |
| Mack David Henry | President and CEO | 0 | $0 | 1 | $62,179 | $-62,179 |
| ORBIMED ADVISORS LLC | 10 percent owner | 0 | $0 | 1 | $900,000 | $-900,000 |
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Over the last 12 months, insiders at PMV Pharmaceuticals, Inc. have bought $0 and sold $1.05M worth of PMV Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at PMV Pharmaceuticals, Inc. have bought $0 and sold $15.07M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,900,000 shares for transaction amount of $34.2M was made by RA CAPITAL MANAGEMENT, L.P. (10 percent owner) on 2020‑09‑29.
| 2025-09-10 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 500,000 1.3373% | $1.80 | $900,000 | +7.09% | |
| 2025-07-01 | Sale | Mack David Henry | President and CEO | 58,411 0.114% | $1.06 | $62,179 | +33.33% | |
| 2025-07-01 | Sale | Ticktin Robert | General Counsel & COO | 23,151 0.0452% | $1.06 | $24,651 | +33.33% | |
| 2025-07-01 | Sale | Jalota Deepika | Chief Development Officer | 33,065 0.0645% | $1.06 | $35,198 | +33.33% | |
| 2025-07-01 | Sale | Carulli Michael | Chief Financial Officer | 28,249 0.0551% | $1.06 | $30,077 | +33.33% | |
| 2024-09-11 | Sale | Jalota Deepika | Chief Development Officer | 7,218 0.0141% | $1.50 | $10,853 | -5.96% | |
| 2024-09-11 | Sale | Carulli Michael | Chief Financial Officer | 2,891 0.0057% | $1.50 | $4,347 | -5.96% | |
| 2023-11-22 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 87,786 0.1816% | $2.23 | $195,763 | -25.56% | |
| 2023-09-15 | Sale | Alland Leila | Chief Medical Officer | 6,291 0.0128% | $6.62 | $41,646 | -74.14% | |
| 2023-09-15 | Sale | Jalota Deepika | Chief Development Officer | 4,104 0.0084% | $6.62 | $27,168 | -74.14% | |
| 2022-05-26 | Sale | OrbiMed Genesis GP LLC | 26,253 0.0695% | $15.93 | $418,210 | -25.36% | ||
| 2022-03-29 | Sale | ORBIMED CAPITAL LLC | 365,000 0.7867% | $21.52 | $7.85M | -45.86% | ||
| 2021-10-06 | Sale | Schroeder Thilo | director | 800 0.0019% | $30.15 | $24,120 | -43.26% | |
| 2021-10-04 | Sale | Schroeder Thilo | director | 100 0.0002% | $30.08 | $3,008 | -43.75% | |
| 2021-10-01 | Sale | Schroeder Thilo | director | 11,541 0.0255% | $30.10 | $347,384 | -46.13% | |
| 2021-09-30 | Sale | Schroeder Thilo | director | 2,978 0.0066% | $30.03 | $89,429 | -45.30% | |
| 2021-09-29 | Sale | Schroeder Thilo | director | 5,708 0.0127% | $30.04 | $171,468 | -45.33% | |
| 2021-09-27 | Sale | Schroeder Thilo | director | 1,753 0.004% | $30.11 | $52,783 | -44.51% | |
| 2021-09-22 | Sale | Schroeder Thilo | director | 100 0.0002% | $30.00 | $3,000 | -41.71% | |
| 2021-09-22 | Sale | LEVINE ARNOLD J | director | 3,500 0.0082% | $30.00 | $105,000 | -41.71% |
| ORBIMED ADVISORS LLC | 10 percent owner | 5975291 11.2294% | $7.11M | 1 | 2 | <0.0001% |
| Mack David Henry | President and CEO | 536133 1.0076% | $637,998.27 | 0 | 6 | |
| Ticktin Robert | General Counsel & COO | 98695 0.1855% | $117,447.05 | 0 | 1 | |
| Jalota Deepika | Chief Development Officer | 89959 0.1691% | $107,051.21 | 0 | 4 | |
| Carulli Michael | Chief Financial Officer | 60146 0.113% | $71,573.74 | 0 | 2 | |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 1710265 3.2141% | $2.04M | 1 | 0 | <0.0001% |
| Schroeder Thilo | director | 1101283 2.0696% | $1.31M | 0 | 62 | |
| Boxer Capital, LLC | 950000 1.7853% | $1.13M | 1 | 0 | <0.0001% | |
| Thompson Peter A. | 475000 0.8927% | $565,250.00 | 1 | 0 | <0.0001% | |
| LEVINE ARNOLD J | director | 409842 0.7702% | $487,711.98 | 0 | 5 | |
| Euclidean Capital LLC | director | 127099 0.2389% | $151,247.81 | 0 | 6 | |
| ORBIMED CAPITAL LLC | 109500 0.2058% | $130,305.00 | 0 | 1 | ||
| OrbiMed Genesis GP LLC | 87786 0.165% | $104,465.34 | 0 | 1 | ||
| ORONSKY ARNOLD L | 55555 0.1044% | $66,110.45 | 1 | 0 | <0.0001% | |
| INTERWEST PARTNERS X LP | director | 55555 0.1044% | $66,110.45 | 1 | 0 | <0.0001% |
| Alland Leila | Chief Medical Officer | 45909 0.0863% | $54,631.71 | 0 | 8 | |
| Kung Winston | COO, CFO | 1600 0.003% | $1,904.00 | 0 | 4 | |
| Heyman Richard A. | director | 0 0% | $0 | 0 | 1 |
$693,326 | 47 | -16.19% | $62.21M | |
$77,146,704 | 43 | 13.28% | $71.58M | |
$24,478,755 | 37 | -34.59% | $53.69M | |
$36,180,184 | 32 | 41.36% | $65.59M | |
$26,765,517 | 25 | -15.03% | $61.3M | |
$2,983,776 | 25 | -16.47% | $50.78M | |
$33,128,160 | 18 | -13.64% | $72.59M | |
$6,720,823 | 16 | -19.92% | $62.97M | |
$17,594,514 | 16 | -20.37% | $53.98M | |
$3,702,538 | 11 | -33.08% | $66.54M | |
$9,999,920 | 10 | -40.03% | $65.83M | |
$45,000,000 | 6 | -31.22% | $74.06M | |
PMV Pharmaceuticals, Inc. (PMVP) | $106,599,960 | 6 | -7.63% | $63.32M |
$26,254,149 | 5 | 49.97% | $61.47M | |
$20,729,984 | 5 | 51.71% | $73.73M | |
$762,555 | 4 | -34.52% | $71.84M | |
$67,369,250 | 3 | -22.09% | $74.79M | |
$73,632,168 | 3 | -63.24% | $56.06M | |
$4,030 | 1 | 9.14% | $53.79M |
| Increased Positions | 31 | +45.59% | 8M | +23.65% |
| Decreased Positions | 27 | -39.71% | 5M | -15.59% |
| New Positions | 18 | New | 6M | New |
| Sold Out Positions | 9 | Sold Out | 2M | Sold Out |
| Total Postitions | 72 | +5.88% | 37M | +8.06% |
| Orbimed Advisors Llc | $7,887.00 | 11.27% | 5.98M | -500,000 | -7.72% | 2025-09-30 |
| Bml Capital Management, Llc | $6,985.00 | 9.99% | 5.29M | +292,000 | +5.84% | 2025-09-30 |
| Tang Capital Management Llc | $6,316.00 | 9.03% | 4.79M | +5M | New | 2025-09-30 |
| Arrowmark Colorado Holdings Llc | $4,358.00 | 6.23% | 3.3M | +113,225 | +3.55% | 2025-09-30 |
| Sio Capital Management, Llc | $3,480.00 | 4.97% | 2.64M | -1M | -29.42% | 2025-09-30 |
| Euclidean Capital Llc | $3,468.00 | 4.96% | 2.63M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $2,855.00 | 4.08% | 2.16M | +9,427 | +0.44% | 2025-09-30 |
| Acadian Asset Management Llc | $2,727.00 | 3.9% | 2.07M | 0 | 0% | 2025-09-30 |
| Stonepine Capital Management, Llc | $1,809.00 | 2.59% | 1.37M | +524,171 | +61.96% | 2025-09-30 |
| Blackrock, Inc. | $1,457.00 | 2.08% | 1.1M | -36,452 | -3.2% | 2025-09-30 |